---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-000432"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:40:17.997001+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MetaVia reports positive Phase 1b results for DA-1726; 9.1% weight loss by Day 54

## Summary
- Statistically significant 9.1% weight loss (21.2 lbs) and 9.8 cm waist reduction by Day 54 in Phase 1b MAD cohort.
- Liver stiffness reduced 23.7% by Day 54 via VCTE, indicating direct hepatic effect.
- Fasted glucose improved 12.3 mg/dL from baseline of 105.3 mg/dL; prediabetic subject HbA1c dropped from 6.0% to 5.5%.
- No treatment-related discontinuations; GI events mild to moderate.
- Plans 16-week titration studies to 48 mg and 64 mg; results expected Q4 2026.

## SEC filing metadata
- accession: 0001104659-26-000432
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926000432/0001104659-26-000432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926000432/tm2528002d7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-000432
- JSON: https://secwatch.observer/filing/0001104659-26-000432.json
- Plain text: https://secwatch.observer/filing/0001104659-26-000432.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.